Lyell Immunopharma, Inc. (LYEL) Free cash flow 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$150.8MFY2025 · since FY2019: $23.4M → -$150.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$150.8M | +7.4% |
| FY2024 | -$162.9M | +2.1% |
| FY2023 | -$166.4M | +14.2% |
| FY2022 | -$193.8M | -1.1% |
| FY2021 | -$191.8M | +9.7% |
| FY2020 | -$212.4M | -1006.5% |
| FY2019 | $23.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Net marginLYEL Gross profitLYEL Gross marginLYEL Operating incomeLYEL Operating marginLYEL Operating cash flowLYEL Capital expendituresLYEL Return on equityLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Total liabilitiesLYEL Shareholders’ equityLYEL overview →